TrialClinical and translational science2024

A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers.

Annemie Deiteren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.